In colorectal cancer [20, 46], ovarian cancer [21], non-small cell lung cancer [17], high-grade invasive uroepithelial carcinoma of the bladder [22], pancreatic cancer [47], and melanoma [48], FAP+CAFs also predict a poorer prognosis for patients. This evidence concerns the gene FAP and non-small cell lung carcinoma.